Reading ECL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ECL free→Reading ECL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ECL free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is neutral, and risk is moderate, while the sector backdrop is a headwind. Peer multiples imply a price about 65% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. Key factors to watch include guidance changes and sector trends, as both could significantly impact ECL's performance. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $265.41. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $265 the market pays 34× p/e — above the 20× p/e peer median but in line with its own 37× history. That premium reflects a durable franchise our peer-anchored $161 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $275–$345. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 65% near-term growth, well above our forecast of about 13%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality. Capped at elevated by the Crisis regime.
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Materials names rated strong grew net income 63% of the time over the next year (vs 54% for the rest of the cohort, n=1093).
Over the trailing year it converted 1.44x of net income into operating cash flow. Historically, Materials names rated neutral grew net income 52% of the time over the next year (vs 55% for the rest of the cohort, n=1297).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.07 → $2.07 (+0.1% / 30d). 3 raised, 1 cut, 19 covering analysts.
1 upgrade, 0 downgrades / 30d, 6 maintained. 74% of analysts rate Buy.
3 PT revisions / 30d. Avg target 23.2% above current price.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$93.
How much price usually moves either way.
On a bad day, this stock has moved -$219.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,009.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Guidance for Q2 EPS shows how well Ecolab can manage rising costs and pricing.
Confirms one read:Q2 adjusted diluted EPS guidance is above $2.12. This shows strong pricing power.
Confirms the other:Q2 adjusted diluted EPS guidance is below $2.02. This shows struggles with costs.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ECL yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On May 19, 2026, Ecolab Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Barclays Capital Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several Underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $1,200,000,000 aggregate principal amount of its 4.600% Notes due 2029 (the “2029 Notes”), $900,…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$275.00 – $345.00 (median $325.00) · 8 analysts · as of 2026-06-10
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Specialty Chemicals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ECL Ecolab | Above typical Show detailsSector percentile: 85 of 100 | expensive | moderate |
SHW Sherwin-Williams | Above typical Show detailsSector percentile: 71 of 100 | full | moderate |
PPG PPG Industries | Above typical Show detailsSector percentile: 90 of 100 | fair | moderate |
LYB LyondellBasell | Typical Show detailsSector percentile: 54 of 100 | — | moderate |
IFF International Flavors & Fragrances | Typical Show detailsSector percentile: 54 of 100 | full | moderate |
10 material management or governance events in the past 24 months, led by executive changes. Historically, Materials names rated volatile grew net income 61% of the time over the next year (vs 51% for the rest of the cohort, n=235).
Not investment advice. As of 2026-06-12.
via XLB
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Met or beat guidance 100% of the last 8 guided quarters · 0.6% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Ecolab aims to maintain its EPS growth trajectory, targeting a 12% to 15% increase for 2026.
Ecolab is focused on managing its capital allocation, including share buybacks and debt management.
Ecolab aims to achieve its quarterly EPS targets, with a focus on consistent performance.
Why it matters: Higher commodity costs may hurt margins and profits for Ecolab.
Confirms:Commodity costs increase by high single digits in Q2.
Disproves:Commodity costs are stable or lower, which helps margins.
Why it matters: Hitting EPS guidance shows Ecolab can keep growing. This is important for investor trust.
Confirms:Q2 2026 EPS reported between $2.02 and $2.12.
Disproves:Q2 2026 EPS falls below $2.02.
Why it matters: Improved revenue growth would signal recovery in Ecolab's performance. This is vital for long-term growth.
Confirms:Q2 2026 revenue growth exceeds 1% year over year.
Disproves:Q2 2026 revenue growth remains below 1% year over year.
Why it matters: Positive cash flow is key for capital allocation and growth. It shows financial health.
Confirms:Cash flow from operations was positive. It was negative $769.2M in 2025-Q4.
Disproves:Cash flow from operations is still negative.
Why it matters: A good buyback can raise stock price. It shows management believes in the company.
Confirms:Stock price increases after the announcement of the $1.2 billion share buyback.
Disproves:Stock price goes down even after the buyback announcement.
Why it matters: Strong growth in Life Sciences helps Ecolab's sales and pricing.
Confirms:Life Sciences organic sales growth above 11% in Q2.
Disproves:Life Sciences organic sales growth is below 8%. This shows possible weakness.
Senior Vice President and Corporate Controller, principal accounting officer — Bryce L. Mewhorter: Mr. Mewhorter was promoted internally to a new senior role.
is furnished and attached as Exhibit (99.1) and (ii) Supplemental Data to be used in connection with the conference call to be held discussing the first quarter results is furnished and attached as Exhibit (99.2), each of which is incorporated by reference herein. Ecolab also will publish the attached exhibits on its website located at www.ecolab.com. Cautionary Statements Regarding Forward Looking Information . Statements contained in this Current Report on Form 8-K, including statements…
Entry into a Material Definitive Agreement . Term Credit Agreement On April 10, 2026, Ecolab Inc. (“Ecolab”) entered into a term credit agreement (the “Credit Agreement”) with various financial institutions, as lenders, and Citibank, N.A., as administrative agent, providing for a $4.75 billion unsecured committed delayed draw term loan credit facility. Under the terms of the Credit Agreement, Ecolab may only use the proceeds of loans under the Credit Agreement to (a) finance the previousl…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth above under